Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ALC
ALC logo

ALC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
69.000
Open
68.800
VWAP
67.29
Vol
3.48M
Mkt Cap
32.61B
Low
65.990
Amount
233.89M
EV/EBITDA(TTM)
12.90
Total Shares
487.70M
EV
37.77B
EV/OCF(TTM)
16.39
P/S(TTM)
3.17
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
Show More

Events Timeline

(ET)
2026-07-06
16:30:00
Alcon and RxSight Announce Collaboration to Develop Adjustable IOLs
select
2026-07-06
16:30:00
Alcon and RxSight Collaborate to Develop Adjustable Intraocular Lenses
select

News

Yahoo Finance
8.5
07-06Yahoo Finance
PinnedAlcon and Mexican Gold Finalize Arrangement Agreement
  • Shareholder Approval: Alcon Silver Corp. received a 66.67% majority approval from shareholders and debenture holders at its annual meeting on July 3, 2026, validating the strategic arrangement with Mexican Gold and marking a significant step in corporate consolidation.
  • Court Approval Application: Alcon plans to apply for a final court order on July 8, 2026, at the Supreme Court of British Columbia to approve the arrangement, which, if granted, will provide legal backing for the transaction and facilitate the merger process.
  • Transaction Closing Timeline: If the final court order is approved, Alcon and Mexican Gold expect to close the transaction around July 15, 2026, laying the groundwork for resource integration and market expansion, thereby enhancing competitiveness in the mining sector.
  • Strategic Development Outlook: The completion of this arrangement agreement not only aids in resource consolidation for Alcon and Mexican Gold but also propels both companies' mineral development efforts in the Americas, strengthening their market position in precious metals and copper projects.
NASDAQ.COM
7.5
07-07NASDAQ.COM
Alcon Partners with RxSight to Develop Adjustable Intraocular Lenses
  • Collaboration Agreement: Alcon has entered a non-exclusive collaboration with RxSight, which will receive an upfront payment of $60 million to support the development of adjustable presbyopia-correcting intraocular lenses, with an additional $140 million contingent on achieving specific milestones, bringing the total potential deal value to $200 million.
  • Technological Integration: This partnership aims to combine RxSight's post-operative light-adjustable technology with Alcon's optical designs for intraocular lenses, enabling more precise visual adjustments for cataract patients opting for these lenses, thereby enhancing surgical outcomes.
  • Market Commercialization Strategy: Alcon will lead global commercialization while RxSight will handle development and manufacturing, with RxSight eligible for royalties on net sales, a division of responsibilities that is expected to accelerate product launch and expand market share.
  • Stock Performance Overview: Alcon's stock has traded between $61.83 and $92.55 over the past year, closing at $68.33, indicating cautious optimism in the market regarding the collaboration's prospects; RxSight's stock has fluctuated between $4.48 and $13.36, closing at $5.60, reflecting market interest in its technology.
Globenewswire
7.5
07-06Globenewswire
Alcon and RxSight Collaborate on Adjustable Intraocular Lens Development
  • Collaboration Agreement: Alcon and RxSight have signed a non-exclusive collaboration agreement to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs), aiming to enhance visual outcomes after cataract surgery by leveraging both companies' strengths in ophthalmic technology.
  • Financial Support: RxSight will receive a $60 million upfront payment to initiate development, with potential additional payments of up to $140 million as development and regulatory milestones are achieved, providing robust financial backing for its technological innovations.
  • Market Leadership: Alcon will lead global commercialization while RxSight will handle development and manufacturing, receiving royalties on net sales; this division of responsibilities is expected to accelerate the market introduction of new products and further solidify both companies' leadership positions in the ophthalmic device market.
  • Patient Benefits: This collaboration will not only provide patients with higher quality customized vision experiences but also promote the adoption of adjustable technologies, addressing the growing market demand and enhancing patients' quality of life.
Newsfilter
7.5
07-06Newsfilter
Alcon and RxSight Collaborate on Adjustable Intraocular Lens Development
  • Collaborative Development: Alcon and RxSight have entered into a non-exclusive agreement to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs), aiming to combine the best technologies from both companies to enhance visual outcomes post-cataract surgery.
  • Funding and Milestones: RxSight will receive a $60 million upfront payment and could earn an additional $140 million upon achieving development and regulatory milestones, providing robust financial support for the technology's development and facilitating its market introduction.
  • Market Leadership: Alcon will lead global commercialization while RxSight will handle development and manufacturing, receiving royalties on net sales; this division of responsibilities is expected to accelerate market penetration of the new product and enhance both companies' competitiveness in the ophthalmic market.
  • Customized Patient Experience: The collaboration underscores the importance of adjustability, which is anticipated to provide more patients with personalized vision solutions, further driving innovation in ophthalmic surgery and improving patient satisfaction.
seekingalpha
9.5
05-07seekingalpha
Alcon Q1 2026 Earnings Call Insights Highlight Strong Market Gains
  • Significant Sales Growth: Alcon reported Q1 sales of $2.7 billion, a 6% increase year-over-year, with surgical equipment sales reaching $253 million, up 23%, indicating strong momentum from the Unity product line that is expected to further enhance market share.
  • Strong New Product Performance: The PanOptix Pro has driven nearly 2 percentage points of growth in the U.S. PC-IOL category, while Tryptyr has captured approximately 4 percentage points of market share just 8 months post-launch, demonstrating the company's ongoing competitiveness in the dry eye segment.
  • Share Repurchase Program: The Board has approved a new $1.5 billion share repurchase program to be executed over the next three years, which is expected to be supported by an estimated $25 million reduction in tariff expenses earmarked for reinvestment, thereby enhancing shareholder value.
  • Optimistic Future Outlook: The company continues to expect sales growth of 5% to 7% for 2026, with an aggregate eye care market growth assumption of 3% to 4%, while core diluted EPS is projected to grow between 10% and 13%, reflecting management's confidence in the market.
NASDAQ.COM
2.0
05-06NASDAQ.COM
Alcon (ALC) Q1 2026 Earnings Call Transcript
Wall Street analysts forecast ALC stock price to rise
13 Analyst Rating
Wall Street analysts forecast ALC stock price to rise
7 Buy
5 Hold
1 Sell
Moderate Buy
Current: 0.000
sliders
Low
78.17
Averages
93.73
High
117.26
Current: 0.000
sliders
Low
78.17
Averages
93.73
High
117.26
Argus
Buy
downgrade
$90 -> $85
AI Analysis
2026-07-02
Reason
Argus
Price Target
$90 -> $85
AI Analysis
2026-07-02
downgrade
Buy
Reason
Argus lowered the firm's price target on Alcon to $85 from $90 and keeps a Buy rating on the shares. Shares trade roughly 35% below all-time highs and at a discount to historical averages, with management having raised earnings guidance to 10%-13% growth in 2026 versus flat 2025 performance, supported by a strong late-stage pipeline with multiple regulatory submissions expected in 2027-2028, reinforcing expectations for sustained longer-term growth, the analyst tells investors in a research note.
Citi
Buy
to
Buy
downgrade
$90 -> $82
2026-06-11
Reason
Citi
Price Target
$90 -> $82
2026-06-11
downgrade
Buy
to
Buy
Reason
Citi lowered the firm's price target on Alcon to CHF 82 from CHF 90 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ALC
Unlock Now

Valuation Metrics

The current forward P/E ratio for Alcon AG (ALC.N) is 20.28, compared to its 5-year average forward P/E of 27.97. For a more detailed relative valuation and DCF analysis to assess Alcon AG's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
27.97
Current PE
20.28
Overvalued PE
32.32
Undervalued PE
23.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
17.73
Current EV/EBITDA
14.23
Overvalued EV/EBITDA
20.20
Undervalued EV/EBITDA
15.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.97
Current PS
2.82
Overvalued PS
4.46
Undervalued PS
3.47

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Find me a trade a d take i
Intellectia · 85 candidates
Region: USVolume: >= -100List Exchange: XNAS, XNYS, XASEMoving Average Relationship: PriceCrossAboveMA20, PriceCrossDownMA20, PriceAboveMA20, PriceAboveMA200, PriceBelowMA20, PriceBelowMA200Is Optionable: TrueSupport Resistance Relationship: PriceBreakResistance, PriceFallBelowSupport, PriceAroundResistance, PriceAroundSupportOne Day Rise Prob: 0 - 100One Day Predict Return: 0.0% - 100.0%One Week Rise Prob: 0 - 100One Week Predict Return: 0.0% - 100.0%Monthly Average Dollar Volume: >= -100Macd: positive, negative, bearish, bullish
Ticker
Name
Market Cap$
top bottom
ABBV logo
ABBV
AbbVie Inc
362.35B
ABT logo
ABT
Abbott Laboratories
182.61B
ARM logo
ARM
Arm Holdings PLC
145.38B
BUD logo
BUD
Anheuser-Busch Inbev SA
133.72B
BTI logo
BTI
British American Tobacco plc
125.56B
ADBE logo
ADBE
Adobe Inc
100.95B
good stocks to buy today go up a lot
Intellectia · 17 candidates
Market Cap: >= 1000.00MRegion: USPrice: $3.00 - $300.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 55One Day Predict Return: >= 2.0%Monthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
SPB logo
SPB
Spectrum Brands Holdings Inc
1.83B
FLNG logo
FLNG
FLEX LNG Ltd
1.53B
ALC logo
ALC
Alcon Inc
41.28B
SAFE logo
SAFE
Safehold Inc
1.16B
COUR logo
COUR
Coursera Inc
1.08B
JBHT logo
JBHT
J B Hunt Transport Services Inc
21.95B
what stocks will bullish today?
Intellectia · 177 candidates
Rsi Category: moderatePrice Change Pct: >= $2.50Relative Vol: >= 1.80Moving Average Relationship: PriceAboveMA20
Ticker
Name
Market Cap$
top bottom
AMGN logo
AMGN
Amgen Inc
185.02B
DHR logo
DHR
Danaher Corp
170.97B
IBKR logo
IBKR
Interactive Brokers Group Inc
128.56B
ARM logo
ARM
Arm Holdings PLC
120.87B
VRTX logo
VRTX
Vertex Pharmaceuticals Inc
117.00B
PBR.A logo
PBR.A
Petroleo Brasileiro SA Petrobras
81.46B
looking for stocks about to break upward
Intellectia · 30 candidates
Market Cap: >= 1000.00MRelative Vol: >= 2Moving Average Relationship: PriceCrossAboveMA20
Ticker
Name
Market Cap$
top bottom
SCHW logo
SCHW
Charles Schwab Corp
180.87B
BTI logo
BTI
British American Tobacco plc
125.29B
ARM logo
ARM
Arm Holdings PLC
120.87B
ALC logo
ALC
Alcon AG
40.09B
CFG logo
CFG
Citizens Financial Group Inc
27.51B
ATO logo
ATO
Atmos Energy Corp
27.23B
best stocks to scalp call options
Intellectia · 55 candidates
Market Cap: >= 1000.00MRsi Category: moderateRelative Vol: >= 2Moving Average Relationship: PriceAboveMA5Is Optionable: True
Ticker
Name
Market Cap$
top bottom
IBKR logo
IBKR
Interactive Brokers Group Inc
128.56B
BTI logo
BTI
British American Tobacco plc
125.29B
ARM logo
ARM
Arm Holdings PLC
120.87B
WM logo
WM
Waste Management Inc
91.25B
TFC logo
TFC
Truist Financial Corp
63.15B
STRC logo
STRC
Strategy Inc
46.15B
give me some swing trades to make today
Intellectia · 128 candidates
Market Cap: >= 1000.00MRsi Category: moderatePrice Change Pct: >= $3.00Relative Vol: >= 1.50Is Optionable: True
Ticker
Name
Market Cap$
top bottom
AMGN logo
AMGN
Amgen Inc
185.02B
DHR logo
DHR
Danaher Corp
170.97B
IBKR logo
IBKR
Interactive Brokers Group Inc
128.56B
ARM logo
ARM
Arm Holdings PLC
120.87B
VRTX logo
VRTX
Vertex Pharmaceuticals Inc
117.00B
ITUB logo
ITUB
Itau Unibanco Holding SA
86.67B
what stock will do good this week
Intellectia · 112 candidates
Market Cap: >= 1000.00MRelative Vol: >= 1.50New High Low: 5_High
Ticker
Name
Market Cap$
top bottom
INTC logo
INTC
Intel Corp
258.77B
TMO logo
TMO
Thermo Fisher Scientific Inc
239.06B
AMGN logo
AMGN
Amgen Inc
185.02B
DHR logo
DHR
Danaher Corp
170.97B
Low logo
Low
Lowe's Companies Inc
155.45B
SBUX logo
SBUX
Starbucks Corp
109.65B
best short term stocks
Intellectia · 54 candidates
Relative Vol: >= 2Rsi 14: 40 - 60Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $0.00Month Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
BTI logo
BTI
British American Tobacco plc
125.29B
ARM logo
ARM
Arm Holdings PLC
120.87B
PBR.A logo
PBR.A
Petroleo Brasileiro SA Petrobras
81.46B
XEL logo
XEL
Xcel Energy Inc
45.26B
ALC logo
ALC
Alcon AG
40.09B
MOG.A logo
MOG.A
Moog Inc
9.94B
good short term stock
Intellectia · 54 candidates
Relative Vol: >= 2Rsi 14: 40 - 60Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $0.00Month Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
BTI logo
BTI
British American Tobacco plc
125.29B
ARM logo
ARM
Arm Holdings PLC
120.87B
PBR.A logo
PBR.A
Petroleo Brasileiro SA Petrobras
81.46B
XEL logo
XEL
Xcel Energy Inc
45.26B
ALC logo
ALC
Alcon AG
40.09B
MOG.A logo
MOG.A
Moog Inc
9.94B
good stock prediction within a week
Intellectia · 34 candidates
Relative Vol: >= 2Weekly Average Turnover: >= 2,000,000Rsi 14: 40 - 60Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
BTI logo
BTI
British American Tobacco plc
125.29B
ARM logo
ARM
Arm Holdings PLC
120.87B
PBR.A logo
PBR.A
Petroleo Brasileiro SA Petrobras
81.46B
XEL logo
XEL
Xcel Energy Inc
45.26B
ALC logo
ALC
Alcon AG
40.09B
EWBC logo
EWBC
East West Bancorp Inc
15.89B

Whales Holding ALC

B
Bellevue Asset Management AG
Holding
ALC
+19.99%
3M Return
S
Sofinnova Investments, Inc.
Holding
ALC
+19.29%
3M Return
L
Lansdowne Partners Limited
Holding
ALC
+15.90%
3M Return
S
Southpoint Capital Advisors LP
Holding
ALC
+15.43%
3M Return
O
Oak Associates, ltd.
Holding
ALC
+13.59%
3M Return
B
BCV Asset Management
Holding
ALC
+11.86%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Alcon AG (ALC) stock price today?

The current price of ALC is 66.87 USD — it has decreased -2.14

What is Alcon AG (ALC)'s business?

Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.

What is the price predicton of ALC Stock?

Wall Street analysts forecast ALC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALC is93.73 USD with a low forecast of 78.17 USD and a high forecast of 117.26 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Alcon AG (ALC)'s revenue for the last quarter?

Alcon AG revenue for the last quarter amounts to 2.71B USD, increased 9.42

What is Alcon AG (ALC)'s earnings per share (EPS) for the last quarter?

Alcon AG. EPS for the last quarter amounts to 0.39 USD, decreased -44.29

How many employees does Alcon AG (ALC). have?

Alcon AG (ALC) has 25942 emplpoyees as of July 08 2026.

What is Alcon AG (ALC) market cap?

Today ALC has the market capitalization of 32.61B USD.